Trial
NCT03329378
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
—
Condition
Locally Advanced Breast Cancer
Intervention
Docetaxel
Why stopped
Data Safety Monitoring Board is in agreement with the study findings so far and the stopping rule has been met, which suspends the study treatment arms in March 2021.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-22